

A MULTISPECIES COMPETITIVE NANOBODY-BASED ELISA FOR THE DETECTION OF ANTIBODIES AGAINST HEPATITIS E VIRUS

Lorena Paola Arce^{1,2}, María Florencia Pavan², Marina Bok³, Silvina Elena Gutiérrez⁴, Silvia Marcela Estein⁴, Agostina Tammone Santos⁴; Walter Ezequiel Condorí⁴; Marcela María Uhart⁵, Viviana Parreño³, María Guadalupe Vizoso-Pinto^{1,*,*} & Lorena Itatí Ibañez^{2,*,*}

¹ Infection Biology Laboratory, Faculty of Medicine and Instituto Superior de Investigaciones Biológicas (INSIBIO), CONICET-UNT, Tucumán, T4000ILI, Argentina

² Laboratorio de Ingeniería de Anticuerpos. Instituto de Química, Física de los Materiales, Medio ambiente y Energía (INQUIMAE- CONICET), Ciudad Autónoma de Buenos Aires, C1428EGA, Argentina

³ InculINTA, Instituto de Virología, Instituto Nacional de Tecnología Agropecuaria (INTA), Husrlingham, 1686, Argentina

⁴ Universidad Nacional del Centro de la Provincia de Buenos Aires, Facultad de Ciencias Veterinarias, Núcleo SAMP. Centro de Investigación Veterinaria de Tandil (UNCPBA-CICPBA-CONICET), Tandil, Buenos Aires, B7000GHG, Argentina


⁵ One Health Institute, School of Veterinary Medicine, University of California Davis, Davis 95616, California, USA

*Correspondence to: Dr. María Guadalupe Vizoso-Pinto Email: mgvizoso@fm.unt.edu.ar


*Correspondence to: Dr. Lorena Itatí Ibañez Email: loreitati@gmail.com

+ These authors contributed equally to this work


Supplementary Information




Supplementary Figure S1. Construction of an immune Nb library. **(A)** Total RNA extracted from llama lymphocytes (sample 1 and 4) was reversed transcribed into cDNA and used as templates for the nested PCR. **(B)** First PCR, a fragment of ~700 bp representing the heavy chain-only antibody repertoire and a fragment of 1,000 bp corresponding to the heavy chain of the conventional antibodies were obtained. **(C)** The band of 700 bp was isolated and used as template for the second PCR, a fragment of 400 bp, corresponding to the VHHs was observed.



Supplementary Figure S2. Screening of specific Nbs against HEV-3 ORF2 protein extracted from periplasm of infected TG1 bacteria. **(A)** ELISA on a plate coated HEV-3 ORF2 protein. **(B)** ELISA on a plate coated with an irrelevant protein (negative control). Specific reaction was developed using horseradish peroxidase (HRP)-linked anti-HA antibody and the TMB substrate. Colonies were picked from agar plates seeded with infected TG1 after different round of panning and elution strategies as follows: A1-A12 and B1-B4 (first round of panning - cell elution); B5-B12 and C1-C12 (first round of panning - trypsin elution); D1-D12 and E1-E4 (second round of panning - cell elution); E5-E12 and F1-F12 (second round of panning - trypsin elution); G1-G12 and H1-H6 (third round of panning - trypsin elution) and H6-H12 (third round of panning – cell elution).



Supplementary Figure S3. Expression and purification of anti-HEV-3 ORF2 Nbs. **(A)** Ten Nbs (two different clones for each Nb) were analyzed by SDS-PAGE and Western blot, proteins with small differences in size were observed. **(B)** Purification of 6 Nbs by affinity chromatography (Ni-NTA resin), FT: flow through, W: wash, and E: elution.



Supplementary Figure S4. Limit of detection of the cELISA. Standard serum for HEV antibodies was diluted and analyzed by developed cELISA.

Supplementary Table 1 Determination of the positive/negative ratio to select the optimal conditions of a novel cELISA for human and swine sera

Antigen HEV-3 ORF2	0.05 ug/ml			0.1 ug/ml			0.2 ug/ml		
	Undiluted	1/2	1/4	Undiluted	1/2	1/4	Undiluted	1/2	1/4
Human									
Positive 1	0.097	0.264	0.424	0.363	0.639	1.546	0.900	1.277	1.487
Negative 1	1.264	1.374	1.424	1.770	1.795	1.783	1.869	1.793	1.866
P/N	0.077	0.192	0.298	0.205	0.356	0.867	0.482	0.712	0.797
Positive 2	0.004	0.057	0.040	0.001	0.011	0.108	-0.001	0.143	0.567
Negative 2	0.966	1.103	1.316	1.592	1.649	1.799	1.755	1.756	1.858
P/N	0.005	0.052	0.031	0.001	0.007	0.06	-0.001	0.081	0.305
Swine									
Positive 1	0.128	0.201	0.384	0.151	0.288	0.548	0.794	1.122	1.417
Negative 1	1.111	1.162	1.136	1.214	1.326	1.254	1.813	1.774	1.686
P/N	0.115	0.173	0.338	0.124	0.217	0.437	0.438	0.632	0.840
Positive 2	0.069	0.081	0.123	0.068	0.074	0.098	0.132	0.249	0.654
Negative 1	1.111	1.162	1.136	1.214	1.326	1.254	1.813	1.774	1.686
P/N	0.062	0.070	0.108	0.056	0.056	0.078	0.073	0.140	0.387

Supplementary Table 2 Reproducibility of novel cELISA

Intra-assay coefficient of variance (CV)							
Serum	Abs 1	Abs 2	Abs 3	Abs 4	Mean	SD	CV%
Positive 1	0.472	0.473	0.464	0.476	0.471	0.010	1.090
Positive 2	0.136	0.137	0.130	0.141	0.136	0.000	3.340
Positive 3	0.051	0.054	0.054	0.054	0.053	0.000	2.820
Positive 4	0.039	0.039	0.042	0.039	0.039	0.000	3.770
Positive 5	0.045	0.045	0.044	0.044	0.044	0.000	1.300
Positive 6	0.048	0.044	0.046	0.044	0.045	0.000	4.210
Positive 7	0.201	0.198	0.204	0.198	0.200	0.000	1.430
Positive 8	0.051	0.048	0.052	0.048	0.049	0.000	4.140
Positive 9	0.041	0.045	0.046	0.042	0.043	0.000	5.470
Negative1	1.695	1.544	1.749	No data	1.662	0.110	6.390
Negative 2	1.759	1.686	1.812	No data	1.752	0.060	3.610
Negative 3	1.860	1.774	1.736	No data	1.790	0.060	3.550
Negative 4	1.643	1.581	1.581	1.513	1.579	0.050	3.360
Negative 5	1.533	1.718	1.601	1.666	1.629	0.080	4.920
Negative 6	1.612	1.632	1.688	No data	1.644	0.040	2.400
Negative 7	1.653	1.766	1.847	1.742	1.752	0.080	4.560
Negative 8	1.495	1.444	1.513	1.447	1.474	0.030	2.350
Negative 9	1.624	1.617	1.581	No data	1.607	0.020	1.440


Inter-assay coefficient of variance (CV)									
Serum	Abs 1	Abs 2	Abs 3	Abs 4	Abs 5	Abs 6	Mean	SD	CV%
Positive 1	0.145	0.160	0.137	0.124	0.127	0.146	0.139	0.010	9.570
Positive 2	0.052	0.062	0.064	0.055	0.067	0.068	0.061	0.010	10.600
Negative1	1.812	1.860	1.825	1.782	1.792	1.856	1.821	0.030	1.770
Negative 2	1.014	1.250	1.345	1.285	1.26	1.02	1.195	0.150	12.130

Supplementary Table 3 Agreements of the cELISA with a commercial ELISA with samples from different species


Commercial ELISA				
		Positive	Negative	Total
cELISA (human)	Positive	5	0	5
	Negative	0	59	59
	Total	5	59	64
	Sensitivity	100 %		
	Specificity	100 %		
cELISA (swine)	Positive	55	2	57
	Negative	1	58	59
	Total	56	60	116
	Sensitivity	98.21 %		
	Specificity	96.67 %		
cELISA (wild boar)	Positive	8	0	8
	Negative	0	14	14
	Total	8	14	22
	Sensitivity	100 %		
	Specificity	100 %		
cELISA (deer)	Positive	1	0	1
	Negative	0	19	19
	Total	1	19	20
	Sensitivity	100 %		
	Specificity	100 %		
cELISA (dog)	Positive	0	0	0
	Negative	1	19	20
	Total	1	19	20
	Sensitivity	0 %		
	Specificity	100 %		
cELISA (mice)	Positive	3	0	3
	Negative	0	2	2
	Total	3	2	5
	Sensitivity	100 %		
	Specificity	100 %		

Unmodified gels

Supplementary Figure S1.




(A) SDS-PAGE and Coomassie blue staining showing the expression and purification of the recombinant HEV-3 ORF2 protein. FT: flow through, W: wash, and E: elution.



(D) Agarose gel showing the ~700 bp PCR fragments corresponding to VHs of variable size amplified from randomly picked individual colonies.

Supplementary Figure S2.




(A) Total RNA extracted from llama lymphocytes (sample 1 and 4) was reversed transcribed into cDNA and used as templates for the nested PCR.

(B) First PCR, a fragment of ~700 bp representing the heavy chain-only antibody repertoire and a fragment of 1,000 bp corresponding to the heavy chain of the conventional antibodies were obtained.


(C) The band of 700 bp was isolated and used as template for the second PCR, a fragment of 400 bp, corresponding to the VHs was observed.

Supplementary Figure S4.



(A) Ten Nbs (two different clones for each Nb) were analyzed by SDS-PAGE and Western blot, proteins with small differences in size were observed.

Purification of anti-HEV-3 ORF2 Nbs



(B) Purification of 6 Nbs by affinity chromatography (Ni-NTA resin), FT: flow through, W: wash, and E: elution.